Patents by Inventor Laura Corral

Laura Corral has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180209961
    Abstract: Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.
    Type: Application
    Filed: November 15, 2017
    Publication date: July 26, 2018
    Inventors: Peter H. SCHAFER, Rajesh CHOPRA, Antonia LOPEZ-GIRONA, Laura CORRAL, Maria Yinglin WANG, Pilgrim JACKSON
  • Patent number: 9857359
    Abstract: Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: January 2, 2018
    Assignee: CELGENE CORPORATION
    Inventors: Peter H. Schafer, Rajesh Chopra, Antonia Lopez-Girona, Laura Corral, Maria Yinglin Wang, Pilgrim Jackson
  • Publication number: 20150203590
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Application
    Filed: April 3, 2015
    Publication date: July 23, 2015
    Inventors: Paul Levi MILLER, Laura CORRAL
  • Patent number: 9000132
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 7, 2015
    Assignee: diaDexus, Inc.
    Inventors: Paul Levi Miller, Laura Corral
  • Publication number: 20140283157
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: diaDexus, Inc.
    Inventors: Paul Levi Miller, Laura Corral
  • Publication number: 20140275485
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Application
    Filed: July 31, 2013
    Publication date: September 18, 2014
    Applicant: diaDexus, Inc.
    Inventors: Paul Levi MILLER, Laura CORRAL
  • Publication number: 20140162282
    Abstract: Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.
    Type: Application
    Filed: June 28, 2013
    Publication date: June 12, 2014
    Applicant: CELGENE CORPORATION
    Inventors: Peter H. SCHAFER, Rajesh Chopra, Antonia Lopez-Girona, Laura Corral, Maria Yinglin Wang, Pilgrim Jackson
  • Patent number: 8637260
    Abstract: Antibodies that are specific for human Ra1A that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: January 28, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William C. Hahn, Laura Corral, Anna A. Sablina
  • Publication number: 20130022539
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.
    Type: Application
    Filed: June 14, 2012
    Publication date: January 24, 2013
    Applicant: diaDexus, Inc.
    Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
  • Publication number: 20120329079
    Abstract: A method for assessing risk of prostate cancer utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination is provided. Also provided is a method for assessing risk of cancer utilizing Pro108 or specific antibodies to Pro108. Antibodies that bind to Pro108 on a mammalian cell in vivo and compositions comprising an anti-Pro108 antibody and a carrier which can be provided in an article of manufacture or a kit are also provided. An isolated nucleic acid encoding an anti-Pro108 antibody, an expression vector comprising the isolated nucleic acid, cells that produce the anti-Pro108 antibodies and a method of producing the anti-Pro108 antibodies as well as methods for use of the antibodies in killing an Pro108-expressing cancer cell and alleviating or treating an Pro108-expressing cancer in a mammal are also provided.
    Type: Application
    Filed: April 3, 2012
    Publication date: December 27, 2012
    Applicant: diaDexus, Inc.
    Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
  • Publication number: 20120263647
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 18, 2012
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
  • Patent number: 8207311
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: June 26, 2012
    Assignee: diaDexus, Inc.
    Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
  • Patent number: 8148093
    Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: April 3, 2012
    Assignee: diaDexus, Inc.
    Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
  • Patent number: 8080650
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: December 20, 2011
    Assignee: diaDexus, Inc.
    Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
  • Publication number: 20110306057
    Abstract: Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
    Type: Application
    Filed: May 16, 2011
    Publication date: December 15, 2011
    Inventors: William C. Hahn, Laura Corral, Anna A. Sablina
  • Publication number: 20100209438
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
    Type: Application
    Filed: October 9, 2009
    Publication date: August 19, 2010
    Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
  • Patent number: 7619068
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: November 17, 2009
    Assignee: diaDexus, Inc.
    Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
  • Publication number: 20090232732
    Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.
    Type: Application
    Filed: October 3, 2007
    Publication date: September 17, 2009
    Inventors: IRIS SIMON, LAURA CORRAL, CHARIS LAWRENSON, NAM KIM, GLENN PILKINGTON, ROBERT L. WOLFERT
  • Publication number: 20090220424
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.
    Type: Application
    Filed: January 15, 2009
    Publication date: September 3, 2009
    Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Weniu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
  • Publication number: 20090136490
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110 expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
    Type: Application
    Filed: November 10, 2005
    Publication date: May 28, 2009
    Applicant: DIADEXUS, INC.
    Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Timothy S. Burcham, Laura Corral, Iris Simon, Jackie Papkoff